Evidence map›Paper›PMID 35920196›Full record

ArticleActa biochimica et biophysica Sinica2022

PHD3 inhibits cell proliferation through hydroxylation of PAX2 at proline 9.

Jie Lun, Yuxin Wang, Qiang Gao, Yu Wang, Hongwei Zhang, Jing Fang

Open access · diamondAbstract read
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Co-Expression of MultipleInternational journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jie LunCancer Institute, the Affiliated Hospital of Qingdao University, School of Basic Medicine of Qingdao University, Qingdao 266061, China.
Yuxin WangShanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai 200031, China.
Qiang GaoShanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai 200031, China.
Yu WangCancer Institute, the Affiliated Hospital of Qingdao University, School of Basic Medicine of Qingdao University, Qingdao 266061, China.
Hongwei ZhangShandong Provincial Maternal and Child Health Care Hospital, Jinan 250014, China.
Jing FangCancer Institute, the Affiliated Hospital of Qingdao University, School of Basic Medicine of Qingdao University, Qingdao 266061, China.
Shanghai Institute of Nutrition and Health · CNShandong Maternal and Child Health Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The oncoprotein transcription factor paired box 2 (PAX2) is aberrantly expressed in cancers, but the underlying mechanism remains elusive. Prolyl hydroxylase 3 (PHD3) hydroxylates the proline residue of HIFα, mediating HIFα degradation. The von Hippel-Lindau protein (pVHL) is an E3 ligase which mediates ubiquitination and degradation of hydroxylated HIFα. PHD3 and pVHL are found to inhibit the expression of PAX2, however, the molecular mechanism is unclear. Here we demonstrate that PHD3 hydroxylates PAX2 at proline 9, which is required for pVHL to mediate PAX2 ubiquitination and degradation. Overexpression of PHD3 enhances prolyl hydroxylation, ubiquitination and degradation of PAX2 with little effect on those of PAX2(P9A). PHD3 does not influence PAX2 expression in

Indexed as

ProlineProlyl HydroxylasesCell ProliferationHydroxylationHypoxia-Inducible Factor 1, alpha SubunitProcollagen-Proline DioxygenaseUbiquitin-Protein LigasesHypoxia-Inducible Factor 1, alpha SubunitProcollagen-Proline DioxygenaseProlineProlyl HydroxylasesUbiquitin-Protein Ligasescell proliferationPAX2PHD3prolyl hydroxylationpVHL

Identifiers

PMID35920196
PMCPMC9827955
OpenAlexW4280565545

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.